1. Scrip
  2. >>COVID-19

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things. 

Scrip Five Must Know Things
Mini Podcast Catch-Up On Last Week's Main Events

Join us in our regular podcast covering major industry events over the past week, in this audio version of Scrip's Five Must-Know Things, this time for the business week ended 13 November 2020.

COVID-19 vaccines dominate developments this time, along with a failed deal in idiopathic pulmonary fibrosis and yet another setback in Alzheimer's disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.